ClinicalTrials.gg
CompletedNCT04410133REVELATEUpdated Aug 28, 2025Results posted

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

A Phase 3 interventional study of 18F fluciclovine in Brain Metastases, sponsored by Blue Earth Diagnostics. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,443 studies in Brain Neoplasms with a site in United States — 229 open to participants now, 352 under way, 18 of them phase 3. Brain Neoplasms · United States.

Enrollment
105th of 1,188
151 · median 30
Started
2020
with 42 others
Phase 3
70 of 1,443
6 open now
Registered
1,117th of 1,443
by date

Among the 1,443 studies in Brain Neoplasms with a site in United States, this one is the 105th largest by enrollment of the 1,188 interventional ones that give a count, is one of 43 that started in 2020, is one of 70 in phase 3, and was the 1,117th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

229 of the 1,443 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

224 more — sign in →

All 229 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,443 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

An open-label, single dose, single arm, prospective, multicenter Phase 3 study to establish the diagnostic performance of 18F fluciclovine positron emission tomography (PET) in detecting recurrent brain metastases after radiation therapy

03

Conditions studied

  • Brain Metastases

Keywords

  • Recurrent Brain Metastases
  • Diagnostic
  • Positron Emission Tomography (PET) Scan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status of 0-1, or 2 if this is an acute deterioration
  2. Previous history of solid tumor of any origin
  3. Histopathological confirmation of the primary solid tumor or a site within 4 years
  4. Previous radiation therapy of brain metastatic lesion(s)
  5. A reference lesion considered by the site investigator to be equivocal for recurrent brain metastasis
  6. Patient requires further confirmatory diagnostic procedures to confirm brain MRI findings and is planned for /neurosurgical intervention as standard of care (SoC) or clinical follow-up as SoC

Exclusion criteria

Exclusion Criteria:

1. Patients with a history of active hematological

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    Patients

    Single intravenous administration of 18F fluciclovine for PET Scan

    Drug: 18F fluciclovine

Interventions

  • 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus

    Also known as: Axumin

06

What researchers measure

Primary outcomes

  1. Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level

    Subject-level PPA and NPA (equivalent to sensitivity and specificity, respectively) of 18F-fluciclovinePET in detecting recurrent brain metastases.

    Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.

Secondary outcomes

  1. Subject Level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)

    Subject-level PPV and NPV of 18F-fluciclovine PET for detecting recurrent brain metastases

    Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.

  2. Lesion-level Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)

    To assess lesion-level PPA \& NPA diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.

    Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.

  3. Lesion-level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)

    To assess lesion-level PPV \& NPV diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.

    Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.

  4. Subject-level Positive Percent Agreement (PPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type

    Sub-group analyses of subject-level PPA \& NPA of fluciclovine (18F) PET, according to primary tumor type.

    Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.

  5. Subject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type

    Sub-group analyses of subject-level PPV \& NPV of fluciclovine (18F) PET, according to primary tumor type.

    Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.

  6. Subject-level Positive Percent Agreement (NPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy

    Sub-group analyses of subject-level PPA \& NPA of fluciclovine (18F) PET, according to concurrent immunotherapy.

    Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.

  7. Subject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy

    Sub-group analyses of subject-level PPV \& NPV of fluciclovine (18F) PET, according to Concurrent Immunotherapy.

    Time frame: MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.

  8. Clinical Usefulness

    Number of days taken by the site to establish presence/absence of metastasis by clinical follow-up.

    Time frame: Follow up through 6 months after PET scan.

  9. Clinical Usefulness

    Proportion of subjects with additional metastases identified on fluciclovine (18F) PET in addition to SoC brain MRI

    Time frame: Follow up through 6 months after PET scan.

  10. Clinical Usefulness

    Proportion of subjects whose prospective diagnostic management plan changed following fluciclovine (18F) PET.

    Time frame: Follow up through 6 months after PET scan.

  11. Inter-reader Reproducibility

    Pairwise comparisons of the central reads for the 3 readers (i.e. Reader 1 vs Reader 2, Reader 1 vs Reader 3, and Reader 2 vs Reader 3) at the subject-level. The percentage of results in agreement (i.e. Positive \[1st reader\] / Positive \[2nd reader\], Negative/Negative) is presented.

    Time frame: PET Scan Day 1

  12. Intra-reader Reproducibility

    Pairwise comparisons of the initial read vs re-read of a subset of PET scans for each reader at the subject-level. The percentage of results in agreement (i.e. Positive \[initial read\] / Positive \[re-read\], Negative/Negative) is presented.

    Time frame: PET Scan Day 1

  13. Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Blood Pressure

    Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.

    Time frame: The vital signs collected between 5 to 60 minutes before and after the PET scan.

  14. Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Heart Rate

    Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.

    Time frame: The vital signs collected between 5 to 60 minutes before and after the PET scan.

  15. Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Respiratory Rate

    Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.

    Time frame: The vital signs collected between 5 to 60 minutes before and after the PET scan.

  16. Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Body Temperature

    Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.

    Time frame: The vital signs collected between 5 to 60 minutes before and after the PET scan.

07

Results

Posted Aug 28, 2025

Participant flow

Participant flow — Overall Study
MilestoneSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Started151
Completed151
Not completed0

Outcome measures

PrimaryPositive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level

Subject-level PPA and NPA (equivalent to sensitivity and specificity, respectively) of 18F-fluciclovinePET in detecting recurrent brain metastases.

Time frame:
MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Reported as:
Number · percentage
Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level
percentageReader 1 - Positive Percent Agreement (PPA)Reader 2 - Positive Percent Agreement (PPA)Reader 3 - Positive Percent Agreement (PPA)Reader 1 - Negative Percent Agreement (NPA)Reader 2 - Negative Percent Agreement (NPA)Reader 3 - Negative Percent Agreement (NPA)
Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level23.8 (12.1 to 39.5)34.1 (20.1 to 50.6)36.6 (22.1 to 53.1)82.6 (74.1 to 89.2)70.9 (61.5 to 79.2)70.9 (61.5 to 79.2)
SecondarySubject Level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)

Subject-level PPV and NPV of 18F-fluciclovine PET for detecting recurrent brain metastases

Time frame:
MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Reported as:
Number · percentage
Subject Level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)
percentageReader 1 - Positive Predictive Value (PPV)Reader 2 - Positive Predictive Value (PPV)Reader 3 - Positive Predictive Value (PPV)Reader 1 - Negative Predictive Value (NPV)Reader 2 - Negative Predictive Value (NPV)Reader 3 - Negative Predictive Value (NPV)
Subject Level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)34.5 (17.9 to 54.3)30.4 (17.7 to 45.8)31.9 (19.1 to 47.1)73.8 (65.0 to 81.3)74.3 (64.8 to 82.5)75.0 (65.6 to 83.0)
SecondaryLesion-level Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)

To assess lesion-level PPA \& NPA diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.

Time frame:
MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Reported as:
Number · percentage
Lesion-level Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)
percentageReader 1 - Positive Percent Agreement (PPA)Reader 2 - Positive Percent Agreement (PPA)Reader 3 - Positive Percent Agreement (PPA)Reader 1 - Negative Percent Agreement (NPA)Reader 2 - Negative Percent Agreement (NPA)Reader 3 - Negative Percent Agreement (NPA)
Lesion-level Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)18.4 (7.3 to 29.4)28.6 (15.8 to 41.4)30.6 (17.7 to 43.5)84.1 (77.4 to 90.7)74.6 (66.6 to 82.7)73.2 (65.0 to 81.4)
SecondaryLesion-level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)

To assess lesion-level PPV \& NPV diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases.

Time frame:
MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Reported as:
Number · percentage
Lesion-level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)
percentageReader 1 - Positive Predictive Value (PPV)Reader 2 - Positive Predictive Value (PPV)Reader 3 - Positive Predictive Value (PPV)Reader 1 - Negative Predictive Value (NPV)Reader 2 - Negative Predictive Value (NPV)Reader 3 - Negative Predictive Value (NPV)
Lesion-level Positive Predictive Value (PPV) and Negative Predictive Value (NPV)29.0 (12.1 to 45.9)28.6 (15.2 to 42.0)28.8 (15.3 to 42.4)74.4 (65.5 to 83.2)74.6 (65.4 to 83.9)74.8 (65.8 to 83.8)
SecondarySubject-level Positive Percent Agreement (PPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type

Sub-group analyses of subject-level PPA \& NPA of fluciclovine (18F) PET, according to primary tumor type.

Time frame:
MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Reported as:
Number · percentage
Subject-level Positive Percent Agreement (PPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type
percentageReader 1 - Positive Percent Agreement (NPA)Reader 2 - Positive Percent Agreement (NPA)Reader 3 - Positive Percent Agreement (NPA)Reader 1 - Negative Percent Agreement (NPA)Reader 2 - Negative Percent Agreement (NPA)Reader 3 - Negative Percent Agreement (NPA)
Melanoma50.0 (1.3 to 98.7)50.0 (1.3 to 98.7)0.0 (0.0 to 84.2)83.3 (58.6 to 96.4)72.2 (46.5 to 90.3)66.7 (41.0 to 86.7)
Breast10.0 (0.3 to 44.5)30.0 (6.7 to 65.3)40.0 (12.2 to 73.8)78.3 (56.3 to 92.5)65.2 (42.7 to 83.6)73.9 (51.6 to 89.8)
Lung Cancer29.2 (12.6 to 51.1)39.1 (19.7 to 61.5)43.5 (23.2 to 65.5)85.4 (72.2 to 93.9)69.4 (54.6 to 81.8)67.3 (52.5 to 80.1)
Non Lung/Breast/Melanoma16.7 (0.4 to 64.1)16.7 (0.4 to 64.1)16.7 (0.4 to 64.1)80.0 (56.3 to 94.3)80.0 (56.3 to 94.3)80.0 (56.3 to 94.3)
SecondarySubject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type

Sub-group analyses of subject-level PPV \& NPV of fluciclovine (18F) PET, according to primary tumor type.

Time frame:
MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Reported as:
Number · percentage
Subject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Tumor Type
percentageReader 1 - Positive Predictive Value (PPV)Reader 2 - Positive Predictive Value (PPV)Reader 3 - Positive Predictive Value (PPV)Reader 1 - Negative Predictive Value (NPV)Reader 2 - Negative Predictive Value (NPV)Reader 3 - Negative Predictive Value (NPV)
Melanoma25.0 (0.6 to 80.6)16.7 (0.4 to 64.1)0.0 (0.0 to 45.9)93.8 (69.8 to 99.8)92.9 (66.1 to 99.8)85.7 (57.2 to 98.2)
Breast16.7 (0.4 to 64.1)27.3 (6.0 to 61.0)40.0 (12.2 to 73.8)66.7 (46.0 to 83.5)68.2 (45.1 to 86.1)73.9 (51.6 to 89.8)
Lung Cancer50.0 (23.0 to 77.0)37.5 (18.8 to 59.4)38.5 (20.2 to 59.4)70.7 (57.3 to 81.9)70.8 (55.9 to 83.1)71.7 (56.5 to 84.0)
Non Lung/Breast/Melanoma20.0 (0.5 to 71.6)20.0 (0.5 to 71.6)20.0 (0.5 to 71.6)76.2 (52.8 to 91.8)76.2 (52.8 to 91.8)76.2 (52.8 to 91.8)
SecondarySubject-level Positive Percent Agreement (NPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy

Sub-group analyses of subject-level PPA \& NPA of fluciclovine (18F) PET, according to concurrent immunotherapy.

Time frame:
MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Reported as:
Number · percentage
Subject-level Positive Percent Agreement (NPA) & Negative Percent Agreement (NPA) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy
percentageReader 1 - Positive Percent Agreement (NPA)Reader 2 - Positive Percent Agreement (NPA)Reader 3 - Positive Percent Agreement (NPA)Reader 1 - Negative Percent Agreement (NPA)Reader 2 - Negative Percent Agreement (NPA)Reader 3 - Negative Percent Agreement (NPA)
Received Concurrent Immunotherapy0.0 (0.0 to 45.9)16.7 (0.4 to 64.1)16.7 (0.4 to 64.1)100.0 (88.4 to 100.0)86.7 (69.3 to 96.2)90.0 (73.5 to 97.9)
Did Not Receive Concurrent Immunotherapy27.8 (14.2 to 45.2)37.1 (21.5 to 55.1)40.0 (23.9 to 57.9)75.9 (65.0 to 84.9)65.0 (53.5 to 75.3)63.8 (52.2 to 74.2)
SecondarySubject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy

Sub-group analyses of subject-level PPV \& NPV of fluciclovine (18F) PET, according to Concurrent Immunotherapy.

Time frame:
MRI for anatomical correlation within 3 days of IMP and PET scan, followed by surgical intervention (if applicable) post-PET scan and follow up through 6 months after PET scan.
Reported as:
Number · percentage
Subject-level Positive Predictive Value (PPV) & Negative Predictive Value (NPV) Diagnostic Performance of Fluciclovine (18F) PET in Detecting Recurrent Brain Metastases in Different Clinical Settings - Concurrent Immunotherapy
percentageReader 1 - Positive Predictive Value (PPV)Reader 2 - Positive Predictive Value (PPV)Reader 3 - Positive Predictive Value (PPV)Reader 1 - Negative Predictive Value (NPV)Reader 2 - Negative Predictive Value (NPV)Reader 3 - Negative Predictive Value (NPV)
Received Concurrent Immunotherapy—20.0 (0.5 to 71.6)25.0 (0.6 to 80.6)83.3 (67.2 to 93.6)83.9 (66.3 to 94.6)84.4 (67.2 to 94.7)
Did Not Receive Concurrent Immunotherapy34.5 (17.9 to 54.3)31.7 (18.1 to 48.1)32.6 (19.1 to 48.5)69.8 (58.9 to 79.2)70.3 (58.5 to 80.3)70.8 (58.9 to 81.0)
SecondaryClinical Usefulness

Number of days taken by the site to establish presence/absence of metastasis by clinical follow-up.

Time frame:
Follow up through 6 months after PET scan.
Reported as:
Median · Days
Clinical Usefulness
DaysSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Clinical Usefulness112 (77.0 to 142.0)
SecondaryClinical Usefulness

Proportion of subjects with additional metastases identified on fluciclovine (18F) PET in addition to SoC brain MRI

Time frame:
Follow up through 6 months after PET scan.
Reported as:
Number · percentage
Clinical Usefulness
percentageSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Clinical Usefulness1.3 (0.2 to 4.7)
SecondaryClinical Usefulness

Proportion of subjects whose prospective diagnostic management plan changed following fluciclovine (18F) PET.

Time frame:
Follow up through 6 months after PET scan.
Reported as:
Number · percentage
Clinical Usefulness
percentageSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Clinical Usefulness26.5 (19.7 to 34.3)
SecondaryInter-reader Reproducibility

Pairwise comparisons of the central reads for the 3 readers (i.e. Reader 1 vs Reader 2, Reader 1 vs Reader 3, and Reader 2 vs Reader 3) at the subject-level. The percentage of results in agreement (i.e. Positive \[1st reader\] / Positive \[2nd reader\], Negative/Negative) is presented.

Time frame:
PET Scan Day 1
Reported as:
Number · percentage
Inter-reader Reproducibility
percentageSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Reader 1 vs Reader 286.1
Reader 1 vs Reader 384.1
Reader 2 vs Reader 391.4
SecondaryIntra-reader Reproducibility

Pairwise comparisons of the initial read vs re-read of a subset of PET scans for each reader at the subject-level. The percentage of results in agreement (i.e. Positive \[initial read\] / Positive \[re-read\], Negative/Negative) is presented.

Time frame:
PET Scan Day 1
Reported as:
Number · percentage
Intra-reader Reproducibility
percentageSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Reader 1 initial read vs re-read93.5
Reader 2 initial read vs re-read93.5
Reader 3 initial read vs re-read100.0
SecondaryAssess the Safety of Fluciclovine (18F) Injection in the Subject Population, Blood Pressure

Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.

Time frame:
The vital signs collected between 5 to 60 minutes before and after the PET scan.
Reported as:
Mean · mmHg
Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Blood Pressure
mmHgSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Systolic Blood Pressure: Pre-IMP Injection128.7 ± 17.25
Systolic Blood Pressure: Post PET Scan132.4 ± 15.25
Systolic Blood Pressure: Change from Pre to Post3.5 ± 12.81
Diastolic Blood Pressure: Pre-IMP Injection75.4 ± 10.69
Diastolic Blood Pressure: Post PET Scan77.0 ± 10.86
Diastolic Blood Pressure: Change from Pre to Post1.5 ± 7.45
SecondaryAssess the Safety of Fluciclovine (18F) Injection in the Subject Population, Heart Rate

Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.

Time frame:
The vital signs collected between 5 to 60 minutes before and after the PET scan.
Reported as:
Mean · beat/min
Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Heart Rate
beat/minSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Heart Rate: Pre-IMP Injection76.2 ± 13.53
Heart Rate: Post PET Scan74.5 ± 12.93
Heart Rate: Change from Pre to Post-1.7 ± 8.43
SecondaryAssess the Safety of Fluciclovine (18F) Injection in the Subject Population, Respiratory Rate

Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.

Time frame:
The vital signs collected between 5 to 60 minutes before and after the PET scan.
Reported as:
Mean · breaths/min
Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Respiratory Rate
breaths/minSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Respiratory Rate: Pre-IMP Injection16.7 ± 2.76
Respiratory Rate: Post PET Scan16.5 ± 2.72
Respiratory Rate: Change from Pre to Post-0.2 ± 1.85
SecondaryAssess the Safety of Fluciclovine (18F) Injection in the Subject Population, Body Temperature

Treatment-emergent adverse events (TEAEs) following 18F-fluciclovine injection in the subject population.

Time frame:
The vital signs collected between 5 to 60 minutes before and after the PET scan.
Reported as:
Mean · degrees Celsius
Assess the Safety of Fluciclovine (18F) Injection in the Subject Population, Body Temperature
degrees CelsiusSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Body Temperature: Pre-IMP Injection36.53 ± 0.419
Body Temperature: Post PET Scan36.53 ± 0.455
Body Temperature: Change from Pre to Post-0.00 ± 0.29

Adverse events

Collected over Treatment emerging AEs were captured within 48 hours.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan0/151 (0%)2/151 (1.3%)15/151 (9.9%)
Most frequent serious events
Most frequent serious events
EventSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
SeizureNervous system disorders1/151
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/151
Most frequent other events
Showing 10 of 16
Most frequent other events
EventSubjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
FatigueGeneral disorders4/151
DizzinessNervous system disorders2/151
NauseaGastrointestinal disorders2/151
Infusion site bruisingGeneral disorders1/151
Injection site reactionGeneral disorders1/151
HeadacheNervous system disorders1/151
ParaesthesiaNervous system disorders1/151
SeizureNervous system disorders1/151
VomitingGastrointestinal disorders1/151
HordeolumInfections and infestations1/151

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
<=18 years0
Between 18 and 65 years81
>=65 years70
Age, Continuous
Age, Continuous(years)Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Mean61.8 ± 11.22
Sex: Female, Male
Sex: Female, Male(Participants)Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Female93
Male58
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Hispanic or Latino18
Not Hispanic or Latino131
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
American Indian or Alaska Native1
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American7
White134
More than one race0
Unknown or Not Reported4
Height (cm)
Height (cm)(cm)Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Mean168.25 ± 10.002
Weight (kg)
Weight (kg)(kg)Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Mean78.72 ± 19.665
Body mass index (kg/m2)
Body mass index (kg/m2)(Kg/m2)Subjects Receiving Single IV Administration of 18F Fluciclovine for PET Scan
Mean27.66 ± 6.314

1 further baseline measures are reported on the registry.

08

Study locations

19 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • University of California, San Francisco
    San Francisco, California 94118, United States
  • John Wayne Cancer Institute at Providence St. John's Health Center
    Santa Monica, California 90404, United States
  • Yale School of Medicine
    New Haven, Connecticut 06519, United States
  • Miami Cancer Institute at Baptist Health, Inc.
    Miami, Florida 33176, United States
  • Medical College of Georgia, Augusta University
    Augusta, Georgia 30912, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70131, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • University of Michigan Rogel Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Washington University School of Medicine-Center for Clinical Imaging Research
    St Louis, Missouri 63110, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • University Hospital Cleveland
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Center for Quantitative Cancer Imaging at Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • West Virgina University Cancer Institute
    Morgantown, West Virginia 26506, United States
09

References and documents

Publications

  • Kotecha R, Aboian M, Nabavizadeh SA, Parent EE, Trifiletti DM, Chao ST. Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation. Neuro Oncol. 2021 Aug 2;23(8):1408-1409. doi: 10.1093/neuonc/noab097. No abstract available. PubMed 34081125 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jun 2023, 31 months.

Results were first posted in Aug 2025, 2 years 2 months after primary completion.

Of 56 phase 3 interventional studies under Brain Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 269. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2020
First posted
Jun 1, 2020
StartActual
Oct 26, 2020
Primary completionActual
Jun 5, 2023
CompletionActual
Jun 5, 2023
Results first posted
Aug 28, 2025
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04410133
Collaborators
Precision For Medicine
Responsible party
Sponsor
First posted
Jun 1, 2020
Start date
Oct 26, 2020
Primary completion
Jun 5, 2023
Completion
Jun 5, 2023
Results posted
Aug 28, 2025
Last update
Aug 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluciclovine F-18

Start the discussion